All In Biotech

Drug Trial Radar · NCT04247542

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection: A Phase 2A Open-Label Segment Followed by a Phase 2B Double-Blind Vancomycin-Controlled Segment

Last checked: Nov 19, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

53

Actual

Start

Mar 6, 2020

Primary completion

Oct 3, 2023

Study completion Nov 15, 2023

Sponsor

Lead sponsor
Acurx Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Jan 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Segments 2A and 2B of this trial evaluate the safety, efficacy, pharmacokinetics, fecal concentrations, and fecal microbiome effects of ACX-362E \[ibezapolstat\] in patients with C. difficile infection (CDI).

Conditions

  • Clostridium Difficile Infection

Interventions

  • IbezapolstatDrug

    Investigational antibacterial agent

  • VancomycinDrug

    Active comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Segment 2A: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI) Per Protocol (PP)/Modified Intent-to-Treat (mITT) PopulationTime frame: 12 days
  2. Segment 2B Per Protocol (PP) Population: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI)Time frame: 12 days
  3. Segment 2B Intent-to-Treat (ITT) Population: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI)Time frame: 12 days

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Acurx Site #118: Dr Janet Reiser

    Scottsdale, Arizona

  • Acurx Site #115: Dr Neera Grover

    Apple Valley, California

  • Acurx Site #125: Dr Karen Simon

    Camarillo, California

  • Acurx Site #111: Dr Jatinder Pruthi

    Lancaster, California

  • Acurx Site #131: Dr Michael Jardula

    Palm Springs, California

  • Acurx Site #129: Dr Stuart Cohen

    Sacramento, California

  • Acurx Site #105

    Doral, Florida

  • Acurx Site #122: Dr Faride Ramos

    Doral, Florida

  • Acurx Site #101: Dr Idalia Acosta

    Miami, Florida

  • Acurx Site #124: Dr Yunior Silva-Barrero

    Miami, Florida

  • Acurx Site #108: Dr Idania Garcia Del Sol

    Miami, Florida

  • Acurx Site #116: Dr Erick Juarez

    Miami, Florida

  • Acurx Site #119: Dr Jorge Paoli-Bruno

    Miami, Florida

  • Acurx Site #107: Dr Belkis Delgado

    Miami Springs, Florida

  • Acurx Site #117: Dr Rafael Companioni

    Panama City, Florida

  • Acurx Site #102: Dr Richard Nathan

    Idaho Falls, Idaho

  • Acurx Site #123: Dr Harry Schrager

    Newton, Massachusetts

  • Acurx Site #104: Dr JeanMarie Houghton

    Worcester, Massachusetts

  • Acurx Site #103: Dr John Pullman

    Butte, Montana

  • Acurx Site #130: Dr Michael DiGiovanna

    North Massapequa, New York

  • Acurx Site #127: Dr Christopher Connolley

    Winston-Salem, North Carolina

  • Acurx Site #126: Dr Andrew Pearson

    Myrtle Beach, South Carolina

  • Acurx Site #114: Dr Eugene Ryan

    Chattanooga, Tennessee

  • Acurx Site #121: Dr Ramesh Gowrappala

    Houston, Texas

  • Acurx Site #120: Dr Vanna Gold

    Lampasas, Texas

  • Acurx Site #113: Dr Jennifer Vincent

    Temple, Texas

  • Acurx Site #110: Dr Val Hansen

    Bountiful, Utah

  • Acurx Site #106: Dr Bezawit Tekola

    Fairfax, Virginia

  • Acurx Site #109: Dr Robert Brennan

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.